Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
KCNJ16 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
KCNJ16 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of KCNJ16 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
KCNJ14 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
KCNJ14 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of KCNJ14 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
KCNJ11 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
KCNJ11 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of KCNJ11 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
KCNJ13 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
KCNJ13 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of KCNJ13 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
KCNJ10 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
KCNJ10 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of KCNJ10 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
KCNJ12 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
KCNJ12 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of KCNJ12 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
KCNJ1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
KCNJ1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of KCNJ1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
KCNH8 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
KCNH8 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of KCNH8 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
KCNIP1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
KCNIP1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of KCNIP1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
KCNIP4 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
KCNIP4 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of KCNIP4 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
KCNH7 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
KCNH7 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of KCNH7 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
KCNIP2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
KCNIP2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of KCNIP2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →